| Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer G Shayan, R Srivastava, J Li, N Schmitt, LP Kane, RL Ferris Oncoimmunology 6 (1), e1261779, 2017 | 281 | 2017 |
| PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer BA Kansy, F Concha-Benavente, RM Srivastava, HB Jie, G Shayan, Y Lei, ... Cancer research 77 (22), 6353-6364, 2017 | 196 | 2017 |
| Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models S Greene, Y Robbins, WK Mydlarz, AP Huynh, NC Schmitt, J Friedman, ... Clinical Cancer Research 26 (6), 1420-1431, 2020 | 177 | 2020 |
| Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma L Tran, CT Allen, R Xiao, E Moore, R Davis, SJ Park, K Spielbauer, ... Cancer immunology research 5 (12), 1141-1151, 2017 | 153 | 2017 |
| A 20-year review of 75 cases of salivary duct carcinoma MR Gilbert, A Sharma, NC Schmitt, JT Johnson, RL Ferris, U Duvvuri, ... JAMA otolaryngology–head & neck surgery 142 (5), 489-495, 2016 | 137 | 2016 |
| Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer SJ Park, W Ye, R Xiao, C Silvin, M Padget, JW Hodge, C Van Waes, ... Oral oncology 95, 127-135, 2019 | 116 | 2019 |
| Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate NC Schmitt, EW Rubel, NM Nathanson Journal of Neuroscience 29 (12), 3843-3851, 2009 | 102 | 2009 |
| Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy NC Schmitt, H Kang, A Sharma Oral oncology 74, 40-48, 2017 | 87 | 2017 |
| Human papillomavirus 16 E 6 antibodies are sensitive for human papillomavirus–driven oropharyngeal cancer and are associated with recurrence KA Lang Kuhs, AR Kreimer, S Trivedi, D Holzinger, M Pawlita, RM Pfeiffer, ... Cancer 123 (22), 4382-4390, 2017 | 76 | 2017 |
| Antibiotic prophylaxis in patients undergoing head and neck free flap reconstruction RM Mitchell, E Mendez, NC Schmitt, AD Bhrany, ND Futran JAMA Otolaryngology–Head & Neck Surgery 141 (12), 1096-1103, 2015 | 75 | 2015 |
| Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen–specific T cells J Friedman, EC Moore, P Zolkind, Y Robbins, PE Clavijo, L Sun, ... Clinical Cancer Research 26 (3), 679-689, 2020 | 61 | 2020 |
| Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk J Li, G Shayan, L Avery, HB Jie, N Gildener-Leapman, N Schmitt, BF Lu, ... Oncoimmunology 5 (10), e1200778, 2016 | 50 | 2016 |
| Immune biomarkers of anti-EGFR monoclonal antibody therapy S Trivedi, F Concha-Benavente, RM Srivastava, HB Jie, SP Gibson, ... Annals of Oncology 26 (1), 40-47, 2015 | 50 | 2015 |
| Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer R Xiao, CT Allen, L Tran, P Patel, SJ Park, Z Chen, C Van Waes, ... Oncoimmunology 7 (9), e1471440, 2018 | 48 | 2018 |
| Atorvastatin is associated with reduced cisplatin-induced hearing loss KA Fernandez, P Allen, M Campbell, B Page, T Townes, CM Li, H Cheng, ... The Journal of clinical investigation 131 (1), 2021 | 43 | 2021 |
| T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response BA Kansy, G Shayan, HB Jie, SP Gibson, YL Lei, S Brandau, S Lang, ... Oncoimmunology 7 (11), e1494112, 2018 | 43 | 2018 |
| ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and … W Ye, S Gunti, CT Allen, Y Hong, PE Clavijo, C Van Waes, NC Schmitt Oncoimmunology 9 (1), 1710398, 2020 | 36 | 2020 |
| Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer RL Ferris, JL Geiger, S Trivedi, NC Schmitt, DE Heron, JT Johnson, S Kim, ... Annals of Oncology 27 (12), 2257-2262, 2016 | 36 | 2016 |
| Characterization of human papillomavirus antibodies in individuals with head and neck cancer KAL Kuhs, M Pawlita, SP Gibson, NC Schmitt, S Trivedi, A Argiris, ... Cancer epidemiology 42, 46-52, 2016 | 36 | 2016 |
| Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV− and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy R Xiao, Y An, W Ye, A Derakhshan, H Cheng, X Yang, C Allen, Z Chen, ... Clinical Cancer Research 25 (21), 6463-6474, 2019 | 29 | 2019 |
